PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1989 October; 82(10): 615–619.
PMCID: PMC1292340

Neuroleptics and psychic indifference: a review.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • CARLSSON A, LINDQVIST M. EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh) 1963;20:140–144. [PubMed]
  • van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966 Apr;160(2):492–494. [PubMed]
  • Andén NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol. 1970;11(3):303–314. [PubMed]
  • Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980 Sep;32(3):229–313. [PubMed]
  • Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978 Apr 22;1(8069):848–851. [PubMed]
  • Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976 Feb;133(2):197–202. [PubMed]
  • Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry. 1973 Jul;29(1):35–40. [PubMed]
  • Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91(4):415–433. [PubMed]
  • Randrup A, Munkvad I. Role of catecholamines in the amphetamine excitatory response. Nature. 1966 Jul 30;211(5048):540–540. [PubMed]
  • Crow TJ. The dopamine hypothesis survives, but there must be a way ahead. Br J Psychiatry. 1987 Oct;151:460–465. [PubMed]
  • Stevens JR. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973 Aug;29(2):177–189. [PubMed]
  • Beninger RJ. The role of dopamine in locomotor activity and learning. Brain Res. 1983 Oct;287(2):173–196. [PubMed]
  • Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev. 1983 Mar;35(1):53–68. [PubMed]
  • Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2(1):19–76. [PubMed]
  • Healy D. Rhythm and blues. Neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders. Psychopharmacology (Berl) 1987;93(3):271–285. [PubMed]
  • Bowers MB, Jr, Heninger GR. Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment. Psychiatry Res. 1981 Jun;4(3):285–290. [PubMed]
  • Miller R. The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness. Psychopharmacology (Berl) 1987;92(4):405–415. [PubMed]
  • Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983 Aug;3(8):1607–1619. [PubMed]
  • Joseph MH, Frith CD, Waddington JL. Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model. Psychopharmacology (Berl) 1979 Jun 21;63(3):273–280. [PubMed]
  • Ridley RM, Baker HF. Is there a relationship between social isolation, cognitive inflexibility, and behavioral stereotypy? An analysis of the effects of amphetamine in the marmoset. Prog Clin Biol Res. 1983;131:101–135. [PubMed]
  • McKenna PJ. Pathology, phenomenology and the dopamine hypothesis of schizophrenia. Br J Psychiatry. 1987 Sep;151:288–301. [PubMed]
  • Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry. 1980 Oct;137:383–386. [PubMed]
  • VENABLES PH, WING JK. Level of arousal and the subclassification of schizophrenia. Arch Gen Psychiatry. 1962 Aug;7:114–119. [PubMed]
  • Hemsley DR. What have cognitive deficits to do with schizophrenic symptoms? Br J Psychiatry. 1977 Feb;130:167–173. [PubMed]
  • Huber G, Gross G, Schüttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6(4):592–605. [PubMed]
  • Ciompi L. The natural history of schizophrenia in the long term. Br J Psychiatry. 1980 May;136:413–420. [PubMed]
  • Kay SR, Opler LA. The positive-negative dimension in schizophrenia: its validity and significance. Psychiatr Dev. 1987 Summer;5(2):79–103. [PubMed]
  • Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987 Aug;151:145–151. [PubMed]
  • Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry. 1985 Mar;146:229–239. [PubMed]
  • Waddington JL, Youssef HA. Late onset involuntary movements in chronic schizophrenia: relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry. 1986 Nov;149:616–620. [PubMed]
  • Strauss JS, Kokes RF, Klorman R, Sacksteder JL. Premorbid adjustment in schizophrenia: concepts, measures, and implications. Part I. The concept of premorbid adjustment. Schizophr Bull. 1977;3(2):182–185. [PubMed]
  • Tantam D. Schizophrenic deterioration. 5. Br J Psychiatry. 1983 Jul;143:83–84. [PubMed]
  • Kirkpatrick B, Johnson M, McGuire K, Fletcher RH. Confounding and the dementia of schizophrenia. Psychiatry Res. 1986 Nov;19(3):225–231. [PubMed]
  • Johnson DA. Studies of depressive symptoms in schizophrenia. Br J Psychiatry. 1981 Aug;139:89–101. [PubMed]
  • Grau BW, Mueser KT. Measurement of negative symptoms. Schizophr Bull. 1986;12(1):7–11. [PubMed]
  • Frith CD. The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med. 1987 Aug;17(3):631–648. [PubMed]
  • Allen HA. Positive and negative symptoms and the thematic organisation of schizophrenic speech. Br J Psychiatry. 1984 Jun;144:611–617. [PubMed]
  • Silverstone T. Dopamine in manic depressive illness. A pharmacological synthesis. J Affect Disord. 1985 May-Jun;8(3):225–231. [PubMed]
  • Healy D, Williams JM. Moods, misattributions and mania: an interaction of biological and psychological factors in the pathogenesis of mania. Psychiatr Dev. 1989 Spring;7(1):49–70. [PubMed]
  • Snyder SH. Neurotransmitters and CNS disease. Schizophrenia. Lancet. 1982 Oct 30;2(8305):970–974. [PubMed]
  • May PR, Van Putten T, Yale C, Potepan P, Jenden DJ, Fairchild MD, Goldstein MJ, Dixon WJ. Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis. 1976 Mar;162(3):177–183. [PubMed]
  • Sacks MH, Carpenter WT, Jr, Strauss JS. Recovery from delusions. Three phases documented by patient's interpretation of research procedures. Arch Gen Psychiatry. 1974 Jan;30(1):117–120. [PubMed]
  • McKenna PJ. Disorders with overvalued ideas. Br J Psychiatry. 1984 Dec;145:579–585. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press